A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 19 Feb 2023 Planned End Date changed from 15 Oct 2023 to 2 Oct 2024.
- 19 Feb 2023 Planned primary completion date changed from 15 Oct 2023 to 2 Oct 2024.
- 02 Nov 2021 Planned initiation date (estimated date for recruitment of the first subject) changed to 15 Dec 2021.